Management of Neuropathic Ocular Pain Associated with Dry Eye Disease in a 5-Year Prospective Cohort

Purpose: This study aimed to assess the long-term management and 5-year evolution of patients with neuropathic ocular pain (NOP) associated with chronic dry eye disease (DED). Methods: Fourteen patients with NOP underwent a 5-year follow-up. Baseline and 5-year assessments included questionnaires on dry eye (Dry Eye Questionnaire 5 [DEQ-5] and Ocular Surface Disease Index), pain (Brief Pain Inventory [BPI]), anxiety/depression disorders (Hospital Anxiety and Depression Scale), and a dedicated questionnaire on NOP characteristics (Neuropathic Ocular Pain Questionnaire), which was developed for this study. Treatment tolerance and effectiveness were rated on a 0–5 scale. Clinical examination, meibography, tear film analysis, corneal nerve density, and inflammation assessment using in vivo confocal microscopy (IVCM) were performed at both time points. Results: Patients were predominantly women (93%) with a mean age of 41 ± 17 years. High rates of comorbid anxiety/depressive disorders (85.7%) and diffuse chronic pain (35.7%) were observed, supporting the need for multimodal care. Over 5 years, significant improvements occurred in mean neuropathic pain scores ( P = 0.005), BPI scores ( P = 0.003), and DEQ-5 scores ( P = 0.041). Clinical parameters remained unchanged, except for a significant decrease in IVCM inflammation score ( P = 0.004). All patients received topical ophthalmic treatments; 78.6% were treated with systemic neuropathic pain relievers, and 64.3% received psychological care. The most effective treatments included artificial tears, cyclosporine eye drops, scleral lenses, oral therapies, and autologous serum eye drops. Conclusion: This study provides the first long-term overview of therapeutic strategies for NOP associated with DED. Findings support a multidisciplinary approach using specific questionnaires and personalized, long-term treatments. However, controlled prospective studies are needed to establish the efficacy of specific therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Journal of Ocular Pharmacology and Therapeutics
Published
2026-09-03
DOI
https://doi.org/10.1177/10807683261475800
Primary Topic
Ocular Surface and Contact Lens
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Management of Neuropathic Ocular Pain Associated with Dry Eye Disease in a 5-Year Prospective Cohort

Serge Doan, Mohamed-Ali Sassi, Catherine Wiart, E. Gabison et al.
Journal of Ocular Pharmacology and Therapeutics
Ocular Surface and Contact Lens
article

Management of Neuropathic Ocular Pain Associated with Dry Eye Disease in a 5-Year Prospective Cohort

Serge Doan, Mohamed-Ali Sassi, Catherine Wiart, E. Gabison, Hélène Rouger, Alice Theuriau, I. Cochereau, Marc Labetoulle
article en

Abstract

Purpose: This study aimed to assess the long-term management and 5-year evolution of patients with neuropathic ocular pain (NOP) associated with chronic dry eye disease (DED). Methods: Fourteen patients with NOP underwent a 5-year follow-up. Baseline and 5-year assessments included questionnaires on dry eye (Dry Eye Questionnaire 5 [DEQ-5] and Ocular Surface Disease Index), pain (Brief Pain Inventory [BPI]), anxiety/depression disorders (Hospital Anxiety and Depression Scale), and a dedicated questionnaire on NOP characteristics (Neuropathic Ocular Pain Questionnaire), which was developed for this study. Treatment tolerance and effectiveness were rated on a 0–5 scale. Clinical examination, meibography, tear film analysis, corneal nerve density, and inflammation assessment using in vivo confocal microscopy (IVCM) were performed at both time points. Results: Patients were predominantly women (93%) with a mean age of 41 ± 17 years. High rates of comorbid anxiety/depressive disorders (85.7%) and diffuse chronic pain (35.7%) were observed, supporting the need for multimodal care. Over 5 years, significant improvements occurred in mean neuropathic pain scores ( P = 0.005), BPI scores ( P = 0.003), and DEQ-5 scores ( P = 0.041). Clinical parameters remained unchanged, except for a significant decrease in IVCM inflammation score ( P = 0.004). All patients received topical ophthalmic treatments; 78.6% were treated with systemic neuropathic pain relievers, and 64.3% received psychological care. The most effective treatments included artificial tears, cyclosporine eye drops, scleral lenses, oral therapies, and autologous serum eye drops. Conclusion: This study provides the first long-term overview of therapeutic strategies for NOP associated with DED. Findings support a multidisciplinary approach using specific questionnaires and personalized, long-term treatments. However, controlled prospective studies are needed to establish the efficacy of specific therapeutic strategies.

Journal of Ocular Pharmacology and Therapeutics
Institut de la Vision (FR), Centre hospitalier national d'ophtalmologie des Quinze-Vingts (FR), Fondation de Rothschild (FR), Bicêtre Hospital (FR)
Good health and well-being
Openalex Percentile: Top 8%
Ocular Surface and Contact Lens
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.